JP2007505601A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP2007505601A
JP2007505601A JP2006525796A JP2006525796A JP2007505601A JP 2007505601 A JP2007505601 A JP 2007505601A JP 2006525796 A JP2006525796 A JP 2006525796A JP 2006525796 A JP2006525796 A JP 2006525796A JP 2007505601 A JP2007505601 A JP 2007505601A
Authority
JP
Japan
Prior art keywords
nucleic acid
muc
protein
hsp70
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505601A5 (https=
Inventor
ハンブリン，ポール，アンドリュー
デル クラ，マリア デ ロス アンヘレス ローチャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2007505601A publication Critical patent/JP2007505601A/ja
Publication of JP2007505601A5 publication Critical patent/JP2007505601A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2006525796A 2003-09-15 2004-09-13 ワクチン Pending JP2007505601A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321614.0A GB0321614D0 (en) 2003-09-15 2003-09-15 Vaccines
PCT/EP2004/010323 WO2005025612A1 (en) 2003-09-15 2004-09-13 Vaccines

Publications (2)

Publication Number Publication Date
JP2007505601A true JP2007505601A (ja) 2007-03-15
JP2007505601A5 JP2007505601A5 (https=) 2007-06-14

Family

ID=29227138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525796A Pending JP2007505601A (ja) 2003-09-15 2004-09-13 ワクチン

Country Status (6)

Country Link
US (1) US20070042047A1 (https=)
EP (1) EP1663301A1 (https=)
JP (1) JP2007505601A (https=)
CA (1) CA2537489A1 (https=)
GB (1) GB0321614D0 (https=)
WO (1) WO2005025612A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
WO2007038083A2 (en) 2005-09-21 2007-04-05 New York University Heat shock proteins from mycobacterium leprae and uses thereof
JP2009544291A (ja) * 2006-07-25 2009-12-17 フォージー ヴァクシンズ ピーティーワイ エルーティーディー ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン
CA2665816C (en) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2021046364A1 (en) 2019-09-06 2021-03-11 Bio Capital Holdings, LLC Genelight cultures and extracts and applications thereof
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510756A (ja) * 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
JP2001512308A (ja) * 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド 合成ｈｉｖ ｇａｇ遺伝子
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US20050031649A1 (en) * 2003-08-06 2005-02-10 Yongli Yu Recombinant fusion proteins comprising BCG heat shock protein 65 and the epitope of MUC1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510756A (ja) * 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
JP2001512308A (ja) * 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド 合成ｈｉｖ ｇａｇ遺伝子
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010010371, Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ， ２０００， Ｖｏｌ．６０， ｐ．１０３５−１０４２ *
JPN6010010375, Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ Ｂｉｏｐｈｙｓｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ， ２００１， Ｖｏｌ．２８３， ｐ．７１５−７２０ *

Also Published As

Publication number Publication date
WO2005025612A1 (en) 2005-03-24
US20070042047A1 (en) 2007-02-22
EP1663301A1 (en) 2006-06-07
GB0321614D0 (en) 2003-10-15
CA2537489A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
US7446185B2 (en) Her2/neu target antigen and use of same to stimulate an immune response
JP3195958B2 (ja) 悪性腫瘍の治療又は予防のための医薬組成物
AU2006299106A1 (en) Compositions and methods for treating tumors presenting survivin antigens
JP2015511602A (ja) リステリアワクチン処理後のサプレッサー細胞機能抑制
JP5017238B2 (ja) 葉酸結合タンパク質の改変体による腫瘍免疫の誘導
RU2303069C2 (ru) Антиген muc1 со сниженным числом повторяющихся vntr-блоков
US20050063952A1 (en) Immunogenic CEA
WO2019101062A1 (zh) 重组疫苗及其应用
JP2007505601A (ja) ワクチン
US20040191761A1 (en) Modified adenoviral E1A constructs and methods of use thereof
US20060147458A1 (en) Vaccines
US10316072B2 (en) Immune modulator for immunotherapy and vaccine formulation
WO2001046228A2 (en) Nucleic acid vaccination
US20060062798A1 (en) Vaccines
US8921534B2 (en) Enhancement of the immune response using CD36-binding domain
WO2024222886A1 (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727